Cargando…
Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients
SARS-CoV-2 infection induces a wide spectrum of neurologic dysfunction that emerges weeks after the acute respiratory infection. To better understand this pathology, we prospectively analyzed of a cohort of cancer patients with neurologic manifestations of COVID-19, including a targeted proteomics a...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833316/ https://www.ncbi.nlm.nih.gov/pubmed/33508216 http://dx.doi.org/10.1016/j.ccell.2021.01.007 |
_version_ | 1783642037421080576 |
---|---|
author | Remsik, Jan Wilcox, Jessica A. Babady, N. Esther McMillen, Tracy A. Vachha, Behroze A. Halpern, Neil A. Dhawan, Vikram Rosenblum, Marc Iacobuzio-Donahue, Christine A. Avila, Edward K. Santomasso, Bianca Boire, Adrienne |
author_facet | Remsik, Jan Wilcox, Jessica A. Babady, N. Esther McMillen, Tracy A. Vachha, Behroze A. Halpern, Neil A. Dhawan, Vikram Rosenblum, Marc Iacobuzio-Donahue, Christine A. Avila, Edward K. Santomasso, Bianca Boire, Adrienne |
author_sort | Remsik, Jan |
collection | PubMed |
description | SARS-CoV-2 infection induces a wide spectrum of neurologic dysfunction that emerges weeks after the acute respiratory infection. To better understand this pathology, we prospectively analyzed of a cohort of cancer patients with neurologic manifestations of COVID-19, including a targeted proteomics analysis of the cerebrospinal fluid. We find that cancer patients with neurologic sequelae of COVID-19 harbor leptomeningeal inflammatory cytokines in the absence of viral neuroinvasion. The majority of these inflammatory mediators are driven by type II interferon and are known to induce neuronal injury in other disease states. In these patients, levels of matrix metalloproteinase-10 within the spinal fluid correlate with the degree of neurologic dysfunction. Furthermore, this neuroinflammatory process persists weeks after convalescence from acute respiratory infection. These prolonged neurologic sequelae following systemic cytokine release syndrome lead to long-term neurocognitive dysfunction. Our findings suggest a role for anti-inflammatory treatment(s) in the management of neurologic complications of COVID-19 infection. |
format | Online Article Text |
id | pubmed-7833316 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78333162021-01-26 Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients Remsik, Jan Wilcox, Jessica A. Babady, N. Esther McMillen, Tracy A. Vachha, Behroze A. Halpern, Neil A. Dhawan, Vikram Rosenblum, Marc Iacobuzio-Donahue, Christine A. Avila, Edward K. Santomasso, Bianca Boire, Adrienne Cancer Cell Article SARS-CoV-2 infection induces a wide spectrum of neurologic dysfunction that emerges weeks after the acute respiratory infection. To better understand this pathology, we prospectively analyzed of a cohort of cancer patients with neurologic manifestations of COVID-19, including a targeted proteomics analysis of the cerebrospinal fluid. We find that cancer patients with neurologic sequelae of COVID-19 harbor leptomeningeal inflammatory cytokines in the absence of viral neuroinvasion. The majority of these inflammatory mediators are driven by type II interferon and are known to induce neuronal injury in other disease states. In these patients, levels of matrix metalloproteinase-10 within the spinal fluid correlate with the degree of neurologic dysfunction. Furthermore, this neuroinflammatory process persists weeks after convalescence from acute respiratory infection. These prolonged neurologic sequelae following systemic cytokine release syndrome lead to long-term neurocognitive dysfunction. Our findings suggest a role for anti-inflammatory treatment(s) in the management of neurologic complications of COVID-19 infection. Elsevier Inc. 2021-02-08 2021-01-16 /pmc/articles/PMC7833316/ /pubmed/33508216 http://dx.doi.org/10.1016/j.ccell.2021.01.007 Text en © 2021 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Remsik, Jan Wilcox, Jessica A. Babady, N. Esther McMillen, Tracy A. Vachha, Behroze A. Halpern, Neil A. Dhawan, Vikram Rosenblum, Marc Iacobuzio-Donahue, Christine A. Avila, Edward K. Santomasso, Bianca Boire, Adrienne Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients |
title | Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients |
title_full | Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients |
title_fullStr | Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients |
title_full_unstemmed | Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients |
title_short | Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients |
title_sort | inflammatory leptomeningeal cytokines mediate covid-19 neurologic symptoms in cancer patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833316/ https://www.ncbi.nlm.nih.gov/pubmed/33508216 http://dx.doi.org/10.1016/j.ccell.2021.01.007 |
work_keys_str_mv | AT remsikjan inflammatoryleptomeningealcytokinesmediatecovid19neurologicsymptomsincancerpatients AT wilcoxjessicaa inflammatoryleptomeningealcytokinesmediatecovid19neurologicsymptomsincancerpatients AT babadynesther inflammatoryleptomeningealcytokinesmediatecovid19neurologicsymptomsincancerpatients AT mcmillentracya inflammatoryleptomeningealcytokinesmediatecovid19neurologicsymptomsincancerpatients AT vachhabehrozea inflammatoryleptomeningealcytokinesmediatecovid19neurologicsymptomsincancerpatients AT halpernneila inflammatoryleptomeningealcytokinesmediatecovid19neurologicsymptomsincancerpatients AT dhawanvikram inflammatoryleptomeningealcytokinesmediatecovid19neurologicsymptomsincancerpatients AT rosenblummarc inflammatoryleptomeningealcytokinesmediatecovid19neurologicsymptomsincancerpatients AT iacobuziodonahuechristinea inflammatoryleptomeningealcytokinesmediatecovid19neurologicsymptomsincancerpatients AT avilaedwardk inflammatoryleptomeningealcytokinesmediatecovid19neurologicsymptomsincancerpatients AT santomassobianca inflammatoryleptomeningealcytokinesmediatecovid19neurologicsymptomsincancerpatients AT boireadrienne inflammatoryleptomeningealcytokinesmediatecovid19neurologicsymptomsincancerpatients |